ArticleGut and liver2009
The clinicopathological significance of tissue levels of hypoxia-inducible factor-1alpha and vascular endothelial growth factor in gastric cancer.
Article in Gut and liver, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 35 citations in OpenAlex.
- Anti-angiogenic Therapy in Patients with Advanced Gastric and Gastroesophageal Junction Cancer: A Systematic Review.Cancer research and treatment · 2017Pooled it
- Randomised phase II study of S-1/cisplatin plus TSU-68 vs S-1/cisplatin in patients with advanced gastric cancer.British journal of cancer · 2013Trial
- The Efficacy of Ramucirumab in the Treatment of Gastric or Gastroesophageal Junction Cancer: A Meta-Analysis of RCTs.Gastroenterology research and practice · 2021Article
- Pazopanib Monotherapy Is Active in Relapsed and Refractory Metastatic Gastroesophageal Adenocarcinoma and Can Produce Durable Response.Journal of gastrointestinal cancer · 2019Article
- Article
- Targeted and novel therapy in advanced gastric cancer.Experimental hematology & oncology · 2019Review
- VEGFA and VEGFR2 RNAscope determination in gastric cancer.Journal of molecular histology · 2018Article
- GRAM domain-containing protein 1B (GRAMD1B), a novel component of the JAK/STAT signaling pathway, functions in gastric carcinogenesis.Oncotarget · 2017Article
- Survival benefit of anti-angiogenic agents in patients with previously treated advanced gastric or gastroesophageal junction cancer: a meta-analysis.Oncotarget · 2017Article
- High-mobility group box-1 contributes tumor angiogenesis under interleukin-8 mediation during gastric cancer progression.Cancer science · 2017Article
- Establishment of a colorectal cancer nude mouse visualization model of HIF-1α overexpression.Oncology letters · 2016Article
- Targeted therapy in gastroesophageal cancers: past, present and future.Gastroenterology report · 2015Article
- Clinical management of advanced gastric cancer: the role of new molecular drugs.World journal of gastroenterology · 2014Review
- Gastric Cancer: New Drugs - New Strategies.Gastrointestinal tumors · 2014Review
- The progress of targeted therapy in advanced gastric cancer.Biomarker research · 2013Article
- Novel targeted agents for gastric cancer.Journal of hematology & oncology · 2012Review
- Chemotherapy for operable gastric cancer: current perspectives.Indian journal of surgical oncology · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
aimsHypoxia-inducible factor-1alpha (HIF-1alpha) is a mediator of tumor progression. Vascular endothelial growth factor (VEGF) is the most potent angiogenic factor known to be induced by HIF-1alpha. We investigated the clinicopathological significance of HIF-1alpha and VEGF levels in biopsied gastric cancer tissue.
methodsEndoscopic biopsy specimens from 67 patients with gastric carcinoma who underwent surgery were available for this study. Semiquantitative RT-PCR was applied to biopsied tumors and normal tissues to determine the expressions of HIF-1alpha and VEGF. The expression levels of HIF-1alpha and VEGF were evaluated using the tumor:normal (T/N) ratios of HIF-1alpha and VEGF mRNA. The clinicopathological variables were reviewed retrospectively.
resultsThe T/N ratios of HIF-1alpha mRNA showed significant correlation with lymph-node metastases, distant metastases, stage, and recurrence within 3 years (p<0.05). The T/N ratios of VEGF mRNA showed significant correlation with lymph-node metastases and distant metastases (p<0.05). There was a significant correlation between the T/N ratios of HIF-1alpha and VEGF mRNA (r=0.72, p<0.01).
conclusionsThe increased expression of HIF-1alpha and VEGF mRNA could reflect aggressive tumor behavior, including the recurrence of gastric cancer. Examination of HIF-1alpha mRNA in biopsy specimens by RT-PCR assay might provide useful preoperative information on tumor aggressiveness.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.